Skip to main content

Sagimet Biosciences Inc.

corporate_fare Company Profile

Sagimet Biosciences Inc.

SGMT·NASDAQ·Life Sciences·CIK 0001400118

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics called fatty acid synthase (FASN) inhibitors. These inhibitors target dysfunctional metabolic and fibrotic pathways in diseases caused by the overproduction of the fatty acid, palmitate. The company's lead drug candidate is denifanstat, an oral, once-daily pill and selective FASN inhibitor. Denifanstat is currently in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer. Sagimet Biosciences Inc. also has a second FASN inhibitor, TVB-3567, which is a potent and selective small molecule FASN inhibitor in development for acne. The company's FASN inhibitors aim to address MASH, an aggressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by excess fat buildup in the liver unrelated to alcohol consumption. A 2023 study indicated MASH affected over 265 million people worldwide in 2019. Denifanstat targets multiple drivers of MASH by reducing steatosis, inflammation, and fibrosis. In the Phase 2b FASCINATE-2 clinical trial, denifanstat met all primary and multiple secondary endpoints in 168 biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52. Topline results were announced in January 2024, and trial results were published in The Lancet Gastroenterology & Hepatology in October 2024.

Sagimet Biosciences Inc. (NASDAQ:SGMT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for SGMT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Sagimet Biosciences Secures $175M in Offering to Fund Dermatology Pipeline and Extend Runway Through 2028
  • Sagimet Biosciences Prices $175M Stock Offering, Signaling Significant Dilution
  • Sagimet Prioritizes Dermatology Pipeline with US Phase 3 for Denifanstat in Acne, Pauses MASH Development
  • Sagimet Biosciences Appoints Experienced CMO Andreas Grauer Following Retirement of Dr. Martins
  • Sagimet Biosciences' Partner Ascletis Receives NMPA Acceptance for Denifanstat NDA in China; Advances MASH Combination Therapy

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$51.04M
Diluted EPS
-$1.58
Op. Cash Flow
-$45.65M
Operating Income
-$56.89M
Cash & Equivalents
$35.02M
Debt / Equity
0.00×
Shares Outstanding
32.35M sh
Source: 10-K · filed 2026-03-11 · accession 0001104659-26-026140
$9.07 -0.11% today
52-week range · as of 2026-11-12 $4.5 – $11.45
Market cap
$648.02M
Volume
1.5M (1.2× avg)
3-mo avg 1.2M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SGMT - Filings & News (Page 2)

SGMT
Apr 27, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.08
Real-time Price: $9.07 info
Change: +$1.99 (+28%) info
Market Cap: $648.02M info
SGMT
Apr 27, 2026, 7:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $5.89
Real-time Price: $9.07 info
Change: +$3.18 (+54%) info
Market Cap: $648.02M info
SGMT
Apr 27, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.89
Real-time Price: $9.07 info
Change: +$3.18 (+54%) info
Market Cap: $648.02M info
SGMT
Apr 21, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.52
Real-time Price: $9.07 info
Change: +$2.55 (+39%) info
Market Cap: $648.02M info
SGMT
Mar 11, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.78
Real-time Price: $9.07 info
Change: +$3.29 (+57%) info
Market Cap: $648.02M info
SGMT
Mar 11, 2026, 7:30 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $5.78
Real-time Price: $9.07 info
Change: +$3.29 (+57%) info
Market Cap: $648.02M info
SGMT
Mar 11, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.63
Real-time Price: $9.07 info
Change: +$3.44 (+61%) info
Market Cap: $648.02M info
SGMT
Feb 02, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.62
Real-time Price: $9.07 info
Change: +$3.45 (+61%) info
Market Cap: $648.02M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets